This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schultz, C. Articles by Rempel, S. A. Search for Related Content PubMed PubMed Citation Articles by Schultz, C. Articles by Rempel, S. A.

Secreted Protein Acidic and Rich in Cysteine Promotes Glioma Invasion and Delays Tumor Growth in Vivo¹

Barbara Jane Levy Laboratory of Molecular Neuro-Oncology, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Health Sciences Center, Detroit, Michigan 48202

Secreted protein acidic and rich in cysteine (SPARC) is highly expressed in human astrocytomas, grades II–IV. We demonstrated previously that SPARC promotes invasion in vitro using the U87MG-derived clone U87T2 and U87T2-derived SPARC-transfected clones, A2b2, A2bi, and C2a4, in the spheroid confrontation assay. Additional in vitro studies demonstrated that SPARC delays growth, increases attachment, and modulates migration of tumor cells in extracellular matrix-specific and concentration-dependent manners. Therefore, we propose that SPARC functionally contributes to brain tumor invasion and delays tumor growth in vivo, and that the effects of SPARC are related to the level of SPARC secreted into the extracellular matrix. To test these hypotheses, we stereotactically injected these clones into nude rat brains (six animals were injected per clone). Animals were sacrificed on day 7 to assess growth and invasion for all clones at the same time in tumor development. To determine whether SPARC delayed but did not inhibit growth, rats were injected with U87T2 or clone A2b2, and the animals were sacrificed on days 9 (U87T2) and 20 (A2b2), when the animals demonstrated neurological deficit. Brains were removed, fixed, photographed, paraffin embedded, and sectioned. Sections were then serially stained with H&E for morphological assessment of invasion and to measure tumor volume, immunohistochemically stained to visualize SPARC, subjected to in situ hybridization with the human AluII DNA-binding probe to identify human cells, and immunohistochemically stained with MIB-1 to measure proliferation index. The results demonstrate that SPARC promotes invasion in vivo at day 7. Both the low (A2bi) and the high (A2b2) SPARC-secreting clones produced invasive tumors, invading with fingerlike projections and satellite masses into adjacent brain, as well as along the corpus collosum. The intermediate SPARC secreting clone (C2a4) primarily migrated as a bulk tumor along the corpus collosum. SPARC significantly decreased tumor growth at day 7, as measured both by adjusted MIB-1 proliferation indices (U87T2 = 95.3 ± 1.4 versus A2bi = 73.4 ± 4.0, A2b2 = 30.8 ± 6.7 and C2a4 = 15.7 ± 13.0) and tumor volumes (U87T2 = 13.4 ± 0.6 mm³ versus A2bi = 4.5 ± 0.6 mm³, A2b2 = 1.1 ± 0.1 mm³, and C2a4 = 0.4 ± 0.1 mm³). Furthermore, SPARC delayed but did not inhibit tumor growth. The patterns of invasion and the extent of growth delay correlated with the level of SPARC expression. We propose that the ability of SPARC to promote invasion depends on the level of its secretion and the resultant modulation of the level of adherence and motility induced. This demonstration that SPARC functionally contributes to brain tumor invasion in vivo suggests that SPARC is a candidate therapeutic target for the design of therapies directed toward inhibition of the invasive phenotype.

This article has been cited by other articles:

				S. C. MALONEY, J.-C. MARSHALL, E. ANTECKA, M. E. ORELLANA, B. F. FERNANDES, C. MARTINS, E. CASTIGLIONE, S. DI CESARE, P. LOGAN, and M. N. BURNIER JR. SPARC is Expressed in Human Uveal Melanoma and its Abrogation Reduces Tumor Cell Proliferation Anticancer Res, August 1, 2009; 29(8): 3059 - 3064. [Abstract] [Full Text] [PDF]

				H. K. Lee, C. Xiang, S. Cazacu, S. Finniss, G. Kazimirsky, N. Lemke, N. L. Lehman, S. A. Rempel, T. Mikkelsen, and C. Brodie GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis Neuro-oncol, January 1, 2008; 10(3): 236 - 243. [Abstract] [Full Text] [PDF]

				N. Said, I. Najwer, and K. Motamed Secreted Protein Acidic and Rich in Cysteine (SPARC) Inhibits Integrin-Mediated Adhesion and Growth Factor-Dependent Survival Signaling in Ovarian Cancer Am. J. Pathol., March 1, 2007; 170(3): 1054 - 1063. [Abstract] [Full Text] [PDF]

				P. O. Sakariassen, L. Prestegarden, J. Wang, K.-O. Skaftnesmo, R. Mahesparan, C. Molthoff, P. Sminia, E. Sundlisaeter, A. Misra, B. B. Tysnes, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells PNAS, October 31, 2006; 103(44): 16466 - 16471. [Abstract] [Full Text] [PDF]

				N. Said and K. Motamed Absence of Host-Secreted Protein Acidic and Rich in Cysteine (SPARC) Augments Peritoneal Ovarian Carcinomatosis Am. J. Pathol., December 1, 2005; 167(6): 1739 - 1752. [Abstract] [Full Text] [PDF]

				Y. Zhou, J. Zhang, Q. Liu, R. Bell, D. A. Muruve, P. Forsyth, M. Arcellana-Panlilio, S. Robbins, and V.W. Yong The chemokine GRO-{alpha} (CXCL1) confers increased tumorigenicity to glioma cells Carcinogenesis, December 1, 2005; 26(12): 2058 - 2068. [Abstract] [Full Text] [PDF]

				J. E. Koblinski, B. R. Kaplan-Singer, S. J. VanOsdol, M. Wu, J. A. Engbring, S. Wang, C. M. Goldsmith, J. T. Piper, J. G. Vostal, J. F. Harms, et al. Endogenous Osteonectin/SPARC/BM-40 Expression Inhibits MDA-MB-231 Breast Cancer Cell Metastasis Cancer Res., August 15, 2005; 65(16): 7370 - 7377. [Abstract] [Full Text] [PDF]

				M. J. Alvarez, F. Prada, E. Salvatierra, A. I. Bravo, V. P. Lutzky, C. Carbone, F. J. Pitossi, H. E. Chuluyan, and O. L. Podhajcer Secreted Protein Acidic and Rich in Cysteine Produced by Human Melanoma Cells Modulates Polymorphonuclear Leukocyte Recruitment and Antitumor Cytotoxic Capacity Cancer Res., June 15, 2005; 65(12): 5123 - 5132. [Abstract] [Full Text] [PDF]

				J. N. Rich, C. Hans, B. Jones, E. S. Iversen, R. E. McLendon, B.K. A. Rasheed, A. Dobra, H. K. Dressman, D. D. Bigner, J. R. Nevins, et al. Gene Expression Profiling and Genetic Markers in Glioblastoma Survival Cancer Res., May 15, 2005; 65(10): 4051 - 4058. [Abstract] [Full Text] [PDF]

				Q. Shi, S. Bao, J. A. Maxwell, E. D. Reese, H. S. Friedman, D. D. Bigner, X.-F. Wang, and J. N. Rich Secreted Protein Acidic, Rich in Cysteine (SPARC), Mediates Cellular Survival of Gliomas through AKT Activation J. Biol. Chem., December 10, 2004; 279(50): 52200 - 52209. [Abstract] [Full Text] [PDF]

				P. A. Puolakkainen, R. A. Brekken, S. Muneer, and E. H. Sage Enhanced Growth of Pancreatic Tumors in SPARC-Null Mice Is Associated With Decreased Deposition of Extracellular Matrix and Reduced Tumor Cell Apoptosis Mol. Cancer Res., April 1, 2004; 2(4): 215 - 224. [Abstract] [Full Text] [PDF]

				E. Sivridis, A. Giatromanolaki, and M. I. Koukourakis "Stromatogenesis" and Tumor Progression International Journal of Surgical Pathology, January 1, 2004; 12(1): 1 - 9. [Abstract] [PDF]

				S. Sangaletti, A. Stoppacciaro, C. Guiducci, M. R. Torrisi, and M. P. Colombo Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma J. Exp. Med., November 17, 2003; 198(10): 1475 - 1485. [Abstract] [Full Text] [PDF]

				S. V. Vadlamuri, J. Media, S. S. Sankey, A. Nakeff, G. Divine, and S. A. Rempel SPARC affects glioma cell growth differently when grown on brain ECM proteins in vitro under standard versus reduced-serum stress conditions Neuro-oncol, October 1, 2003; 5(4): 244 - 254. [Abstract] [PDF]

				B. Hu, P. Guo, Q. Fang, H.-Q. Tao, D. Wang, M. Nagane, H.-J. Su Huang, Y. Gunji, R. Nishikawa, K. Alitalo, et al. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2 PNAS, July 22, 2003; 100(15): 8904 - 8909. [Abstract] [Full Text] [PDF]